Chimerix Inc

Chimerix — Investor Presentation (May 2023)

41 slides from Chimerix's investor presentation, May 4, 2023

  1. Slide 1: Chimerix Corporate Presentation Q2 2023

    Chimerix Corporate Presentation Q2 2023

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking stateme

  3. Slide 3: Investment highlights

    3 Investment highlights • Terminal disease with no effective therapeutic options • High awareness for program within neuro-oncology community • U.S. patent exclusivity through at least 2037 • Global revenue potential of ~$750m in first indication alone • Phase 2 study designed to isolate single agen

  4. Slide 4: Deep pipeline across all development stages

    4 Preclinical Phase 1 Phase 2 Registrational Approved Collaborators Smallpox (orphan drug designation) SARS-CoV-2 IND-enabling studies CNS4 tumors IITs- signal finding, multiple oncology indications/combinations H3 K27M-mutant glioma (orphan drug,1 fast track2 and rare pediatric disease designations

  5. Slide 5: ONC201 (dordaviprone) Phase 2 Efficacy Analysis

    ONC201 (dordaviprone) Phase 2 Efficacy Analysis

  6. Slide 6: H3 K27M-mutant diffuse glioma: high unmet need

    6 • H3 K27M mutation is predominantly found among diffuse midline gliomas (DMGs) in young adults and children • Frontline radiotherapy remains standard of care with transient benefit; resection often not feasible • DMGs harboring the H3 K27M mutation are WHO Grade IV; historically invariably lethal

  7. Slide 7: Phase 2 efficacy for ONC201 in recurrent H3 K27M DMG

    7 • ONC201 monotherapy exhibited durable, clinically meaningful efficacy in recurrent H3 K27M-mutant DMG - Overall Response Rate (ORR) of 30% (95% CI: 18 - 45%) by RANO HGG and/or LGG dual reader BICR - RANO-HGG criteria assessed by dual reader BICR • ORR 20% (95% CI: 10 – 34%) • Median Duration of

  8. Slide 8: FDA-aligned criteria for Phase 2 efficacy analysis

    8 Objective • To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma Eligibility • Age ≥2yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018 • Diffuse glioma with a known H3 K27M mutation and involvement of a midline structure of the

  9. Slide 9: ONC201 waterfall plot – 30% RANO HGG / LGG response

    9 • Strict selection criteria to ensure responses attributable to single agent treatment • Responses require both imaging and clinical criteria • Dual reader blinded independent central review (BICR) • Growing consensus that assessment of enhancing and non-enhancing disease (RANO-HGG and RANO-LGG cr

  10. Slide 10: RANO-HGG responses observed across age groups

    10 RANO-HGG responses observed across age groups Responses by age group: <18 years: 1/4 (25%) 18-40 years: 5/32 (16%) >40 years: 4/14 (29%) RANO-HGG response of 8-year-old subject suggests activity in this population ONC201 Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant Diffuse Midline G

  11. Slide 11: RANO HGG response correlation to performance status

    11 RANO HGG response correlation to performance status (PS) supports early-line trial Predictably, patients with higher PS were more likely to respond to treatment 100: 1/2 (50%) 90: 4/14 (29%) 80: 4/20 (20%) 70: 1/7 (14%) 60: 0/7 (0%) Supports hypothesis that treating earlier in disease course may

  12. Slide 12: Clinically meaningful and durable RANO-HGG responses

    12 Clinically meaningful and durable RANO-HGG responses SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR) Only patients with measurable target enhancing lesions by BICR at baseline and with post-baseline evaluations are included. Three patients did not have on-treatm

  13. Slide 13: ONC201 safety

    13 Treatment-related Adverse Events, Integrated Safety Data Set, (N=211 glioma patients) 2 Related TEAEs All grades Grade > 3 Any Treatment-related AE 55.5% 11.8% Fatigue 21.8% 2.8% Nausea 20.4% 0 Vomiting 14.2% 0.5% Headache 8.5% 0.5% Lymphocyte count decreased 6.6% 0.5% Decreased appetite 5.7% 0 W

  14. Slide 14: RANO responses correspond with survival & clinical benefit

    14 All patients RANO HGG Responders RANO HGG and/or LGG Responders N 50 10 15 PFS at 12 months (number of patients censored) 30%1 90% (0) 67% (2) OS at 24 months (number of patients censored)2 35%1 80% (2) 53% (5) Corticosteroids response3 (number of patients evaluable) 47% (15) 100% (4) 100% (5) Pe

  15. Slide 15: Strong rationale for phase 3 success relative to recent GBM trials

    15 Experimental Agent Ph2 Design Biomarker Response criteria Confounded by anti-angiogenic pseudo response ORR Duration of response 6 month PFS Approved? ONC201– Ph2 rDMG Single agent H3 K27M RANO BICR No 20-30% 11.2 35% To be determined Temozolomide Single agent - Levin No 5% ? 21% Yes (OS) Bevaciz

  16. Slide 16: ONC201 Phase 3 ACTION Study Summary

    ONC201 Phase 3 ACTION Study Summary

  17. Slide 17: Pivotal Phase 3 ACTION trial design

    17 Now enrolling, a randomized, double-blind, placebo-controlled, multicenter international study in 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation. Pivotal Phase 3 ACTION trial design 1. Excludes DIPG and spinal tumors • H3 K27M-mutant diffuse glioma1 • Radiatio

  18. Slide 18: Unique aspects of ONC201 data support translation to phase 3 success

    18 Multiple unique aspects to ONC201 data support translation to phase 3 success Isolated, durable single agent activity Consistency across multiple endpoints Enhanced activity not required, but likely • Responses not confounded by combination treatments • Responses were gradual, durable, and multi-

  19. Slide 19: Design provides multiple paths for success

    19 Design provides multiple paths for success Interim data expected in early 2025 and final data in 2026 Second OS Interim • ~246 events • Success at HR=0.64 Final OS • ~327 events • Success at HR=0.73 PFS by RANO HGG(2) • ~286 events • Success at HR=0.68 1. Overall Survival (OS) 2. Progression-free

  20. Slide 20: Potential to increase ONC201 efficacy with dose schedule

    20 Potential to increase ONC201 efficacy with dose schedule • Once per week ONC201 dosing effective as monotherapy in Phase 2 studies • Twice per week dosing on two consecutive days expected to increase duration of therapeutic exposure - Increased exposure time can increase glioma sensitivity to ONC

  21. Slide 21: ONC201 Market Opportunity Assessment

    ONC201 Market Opportunity Assessment

  22. Slide 22: H3 K27M-mutant glioma: rapid ramp to peak revenue expected

    22 • No approved therapies for H3 K27M mutant glioma, ONC201 is the leading program targeting this mutation globally • Potential market opportunity ~$750 million • Approximately 5,000 patients in top seven markets • Ultra-orphan indication drug pricing • H3 K27M mutations most often in children / yo

  23. Slide 23: Regulatory designations

    23 Regulatory designations 1. Subject to continuation of Rare Pediatric Disease Voucher Program and proceeds from voucher will be split 50/50 with legacy Oncoceutics shareholders US - Orphan Drug Designation (ODD) (treatment of glioblastoma and treatment of malignant glioma) EU - ODD for treatment o

  24. Slide 24: ONC201 interim efficacy results in dopamine-secreting tumors outside the brain

    24 • Single agent responses in Ph 2 neuroendocrine trial of ONC201 observed in subset (paraganglioma) • Paraganglioma are adrenal-related tumors with elevated DRD2 expression • Five patients have been treated > 1 year • Fewer short-term and potential long-term toxicities than other paraganglioma the

  25. Slide 25: ONC201 Mechanism of Action

    ONC201 Mechanism of Action

  26. Slide 26: ONC201 directly engages DRD2 and ClpP

    26 • ONC201 can selectively induce apoptosis in cancer cells by altering activity of two proteins • DRD2 antagonism - DRD2 is a G protein-coupled neuroreceptor that regulates Ras signaling - ONC201 antagonizes DRD2, inhibiting Ras signaling pathways • ClpP agonism - ClpP normally degrades misfolded

  27. Slide 27: H3 K27M glioma primed for ONC201 sensitivity

    27 H3 K27M glioma primed for ONC201 sensitivity Chi et al., Society of Neuro-Oncology, 2017; Piccardo et al., Eur J. Nucl Med Mol Imaging, 2019 Ex vivo high grade glioma growth sensitivity to ONC201 by H3 status DRD2 pathway inhibited by ONC201 is enriched in H3 K27M glioma H3 K27M glioma often loca

  28. Slide 28: H3 K27M central characteristic reversed by ONC201

    28 H3 K27M central characteristic reversed by ONC201 https://www.cell.com/trends/cancer/fulltext/S2405-8033%2819%2930202-X, Zhang et al, Science Translational Medicine, 2023; Koshmann et al, AACR 2023 H3 K27M causes loss of global H3 K27 trimethylation (H3 K27me3-loss) Removal of H3 K27M mutation re

  29. Slide 29: ONC206

    ONC206

  30. Slide 30: ONC206: oral brain penetrant DRD2 antagonist + ClpP agonist

    30 ONC206: oral brain penetrant DRD2 antagonist + ClpP agonist 1. PDB 6CM4 2. PDB 6DL7 DRD21 ClpP2 ONC206• Second generation imipridone designed to expand to new indications • Efficacy in cell culture, xenograft and transgenic central nervous system (CNS) and other tumor models • Oral dose escalatio

  31. Slide 31: ONC206 monotherapy active in models of CNS and other cancers

    31 CNS Tumors Glioblastoma1 Medulloblastoma2 ONC206 monotherapy active in models of CNS and other cancers 1. Theeler et al, SNO 2020 2. Malhotra et al, ISPNO, 2020 3. Hu et al, Cancers 2020 4. Tucker et al, American Journal of Cancer Research, 2022 Weeks P<0.05 ARK1 Human Endometrial Cancer Xenograf

  32. Slide 32: Dose intensification expected to enhance therapeutic exposure

    32 • Consecutive day dosing may increase therapeutic response - In vitro data demonstrates enhanced efficacy with 72 hour sustained exposure - Toxicology data enables safe escalation to more prolonged exposures • PK models from ongoing adult Phase 1 trial data suggest a therapeutic and safe exposure

  33. Slide 33: ONC206 dose escalation: pediatric and adult CNS tumors

    33 ONC206 dose escalation: pediatric and adult CNS tumors • Monotherapy dose escalation trials enrolling in parallel for adult and pediatric CNS tumors • Response reported by investigator from early cohort (100mg QW) without H3 K27M mutation - 18-year-old patient with recurrent temporal lobe gliobla

  34. Slide 34: ~30,000 new cases of GBM annually in top 7 markets; >$2Bn opportunity

    34 • GBM is a rapidly progressive disease with low survival rates, few drug approvals last 25 years: - Temozolomide (TMZ) approved 1999 - Bevacizumab approved 2009 • Existing therapies rarely offer durable effect - 3-year survival from diagnosis • Chimerix retains global operational rights to ONC206

  35. Slide 35: Preclinical Development ONC212 and CMX521

    Preclinical Development ONC212 and CMX521

  36. Slide 36: ONC212: GPR132 + ClpP Agonist

    36 • Distinct molecular target (GPR132) and efficacy profile relative to ONC201/ONC206 • Efficacy in preclinical models of advanced cancers • GLP-tox studies complete, potential to advance to IND • Partnerships established for early-stage clinical trials with Brown University and MD Anderson Cancer

  37. Slide 37: CMX-521: anti-SARS-CoV-2 preclinical activity

    37 • Ribonucleoside analog that is a viral polymerase inhibitor - Inhaled nebulized liquid aerosol formulation; minimal systemic exposure • Monotherapy efficacy in mouse-adapted SARS-CoV-2-MA10 model across multiple endpoints - Lung viral titer - Viral RNA parallel viral lung titer (plaque forming u

  38. Slide 38: Corporate Update

    Corporate Update

  39. Slide 39: TEMBEXA deal term summary

    39 Emergent BioSolutions is an experienced biodefense company collaborating with government agencies to protect public health Terms summary: • $238 million received upfront at closing in Q3 2022 • Up to an additional $124 million in potential BARDA procurement milestones • 20% royalty on future U.S.

  40. Slide 40: Financial strength supports development through key catalysts

    40 Financial strength supports development through key catalysts Low barriers to commercial potential for ONC201 High probability of success for Phase 3 ACTION study of ONC201 Corporate capability and financial flexibility Fully funded Ph 3 program with multiple potential paths to approval First-Lin

  41. Slide 41: Chimerix

    Chimerix Corporate Presentation

Chimerix — Investor Presentation (May 2023) on 6ix